INSULIN RESISTANCE AND ATHEROSCLEROSIS STUDY (IRAS)

胰岛素抵抗和动脉粥样硬化研究（IRAS）是一项多中心 胰岛素抵抗与心血管疾病关系的研究 三种族（非裔美国人， 西班牙裔和非西班牙裔白色）人口， 基线。选择研究人群以确保足够数量的 性别和葡萄糖耐量组（正常，受损）中的参与者 葡萄糖耐量和非胰岛素依赖型糖尿病[NIDDM]）。 IRAS是第一个大型流行病学研究，包括详细的 测量胰岛素敏感性和分泌。前四 多年来，IRAS的研究人员成功地设计了 实施了研究的第一阶段-对 1 626人参加。目前的提议要求增加5个员额， 预期的后续行动和重新审查的资金 IRAS队列。申请的供资期包括三个阶段。 在第一阶段（Y 05和Y 06），研究者建议进行 两个子研究。第一个将解决胰岛素的测量 对NIDDM患者的敏感性。本研究将评估四个 测量50例非IRAS患者胰岛素敏感性的替代技术 志愿者第二个子研究将审查方法问题， 三种族人群肥胖和体脂分布的测量 240名IRAS参与者。此外，所有IRAS参与者将 每年因心血管事件和其他重大健康问题联系 事件在第二阶段（Y 07和Y 08），进行随访检查 IRAS队列的目标是确定 胰岛素敏感性变化的预测因子，心血管危险因素， 动脉粥样硬化发展的指标，以及心血管事件 事件此外，在前四个赛季（Y 05 -08）， 将继续致力于分析和报告跨- 第一次IRAS检查的截面数据。最后阶段（Y 09） 将包括数据库关闭和存档，以及分析和报告 纵向结果。

The Insulin Resistance and Atherosclerosis Study (IRAS) is a multicenter study of the relationship between insulin resistance and cardiovascular disease (CVD) and its risk factors in a tri-ethnic (African-American, Hispanic, and non-Hispanic white) population aged 40 to 69 years at baseline. The study population was selected to insure adequate numbers of participants within gender and glucose tolerance groups (normal, impaired glucose tolerance, and non-insulin dependent diabetes mellitus [NIDDM]). IRAS is the first large epidemiologic study to include detailed measurements of insulin sensitivity and secretion. During the first four years of funding the IRAS investigators successfully designed and implemented the first phase of the study--a cross-sectional evaluation of 1,626 participants. The current proposal requests an additional five years of funding for the prospective follow-up and reexamination of the IRAS cohort. The requested funding period consists of three phases. During the first phase (Y05 and Y06), the investigators propose to conduct two substudies. The first will address the measurement of insulin sensitivity in individuals with NIDDM. This study will evaluate four alternative techniques for measuring insulin sensitivity in 50 non-IRAS volunteers. The second substudy will examine methodologic issues in the measurement of obesity and body fat distribution in a tri-ethnic subgroup of 240 IRAS participants. In addition, all IRAS participants will be contacted annually for incident cardiovascular and other major health events. During the second phase, (Y07 and Y08), a follow-up examination of the IRAS cohort will be conducted with the goal of determining predictors of changes in insulin sensitivity, cardiovascular risk factors, measures of atherosclerosis development, and incident cardiovascular events. Additionally, throughout the first fours (Y05-08) a major effort will continue to be devoted to the analysis and reporting of the cross- sectional data from the first IRAS examination. The final phase (Y09) will include database closure and archival, and analysis and reporting of the longitudinal results.